The UCPMP is voluntary and there is no legal penalty for violating the code
Company left with low-margin brands in India after selling profitable ones
The government on Friday launched diabetes drug Sitagliptin and its combinations at rates as low as Rs 60 per pack of ten, which will be sold at generic pharmacy stores, Janaushadhi Kendras. The Pharmaceuticals & Medical Devices Bureau of India (PMBI) has included new variants of Sitagliptin and its combination across its Jan Aushdhi Kendras, the Ministry of Chemicals and Fertilisers said in a statement. The maximum retail price for a pack of ten Sitagliptin phosphate tablets 50 mg is Rs 60, while the same for Sitagliptin phosphate tablet 100 mg is Rs 100. Combination of Sitagliptin and Metformin Hydrochloride tablets of 50mg/500mg is priced at Rs 65 for a pack of ten and Sitagliptin Metformin hydrochloride tablets of 50mg/1000mg strength comes for Rs 70 for the same quantity. "All these variants are available at 60 per cent to 70 per cent lesser prices than branded variants as they are available in price band of Rs 162 to Rs 258 at other medical stores," the statement said. PMBI
Vertical witnesses 25% CAGR in 5 yrs
The Hyderabad-based company claimed that BBV154 is proven to be safe, well-tolerated and immunogenic in the subjects under controlled clinical trials
More than 200,000 candidates appeared for the AP EAPCET exam this year
The product -- Ayouthveda -- has been prepared by adding time-tested herbs
Dr Reddy's Laboratories on Tuesday said it has received approval from the US health regulator to market Lenalidomide capsules
Hospitals to gain most with up to 3.5% dip on cost of funds; may add half a million beds, says rating agency
At least four companies say they are working 'very rapidly' to find a vaccine.
Experts expect change in strategy for a focus on high-margin products, rather than multiple brand launches
Drugmakers in Medak, including large Indian firms Dr Reddy's Laboratories, Aurobindo Pharma and Hetero Drugs
Union government is allegedly cutting down support to bulk drug manufacturing from a proposed outlay of Rs 5,000 crore to nearly Rs 600 crore